Amgen Phase III Data Could Add Second Indication To Uplizna’s Label

 
• By Joseph Haas
Rare disease
Amgen's hopes Uplizna can become the first approved therapy for IgG4-RD • Source: Shutterstock

More from Clinical Trials

More from R&D